Phase II Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
Latest Information Update: 28 Mar 2022
At a glance
- Drugs Avelumab (Primary) ; Axitinib (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- Acronyms GliAvAx
- 04 Jun 2019 Results assessing the outcome of patients with recurrent glioblastoma, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 22 Jan 2019 Status changed from recruiting to completed.
- 05 Jun 2018 Results (as of Jan 2018, n=32, 280 treatment weeks in Cohort A and B) assessing safety of axitinib plus avelumab in patients with recurrent glioblastoma, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.